Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net

Intangibles, net

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

9. Intangibles, net

The table below provides a summary of the JMC intangible asset as of March 31, 2019 and December 31, 2018, respectively:

	Estimated Useful		March 31,		December 31,
($ in thousands)	Lives (in years)		2019		2018
Ceracade®		3	$	300	$	300
Luxamend®		3		50		50
Targadox®		3		1,250		1,250
Exelderm®		3		1,200		1,200
Total				2,800		2,800
Accumulated amortization				1,617		1,383
Net intangible assets			$	1,183	$	1,417

The table below provides a summary for the three months ended March 31, 2019, of JMC recognized expense related to its product licenses, which was recorded in costs of goods sold on the Condensed Consolidated Statement of Operations:

( $ in thousands)	Intangible Assets
Beginning balance at January 1, 2019	$	1,417
Amortization expense		(234	)
Ending balance at March 31, 2019	$	1,183

The future amortization of these intangible assets is as follows:

							Total
($ in thousands)	Ceracade®		Targadox®		Exelderm®		Amortization
For the nine-months ending December 31, 2019	$	8	$	208	$	300	$	516
December 31, 2020		–		–		400		400
December 31, 2021		–		–		267		267
Total	$	8	$	208	$	967	$	1,183